К содержанию
Dr. Tara EinullaevaMedical oncologist

Cancer glossary

PD-L1 on a pathology report: what TPS and CPS mean and why

What PD-L1 means on an IHC report: how TPS differs from CPS, which cutoffs are used in lung and other cancers, and how the result affects immunotherapy.

Written and medically reviewed by

Dr. Tara Einullaeva

Medical oncologist, 9 years in practice. Credentials · reviewed 17 October 2026

In short

PD-L1 is a protein that tumors use to switch off the immune cells attacking them. Its level is measured by immunohistochemistry and reported as TPS or CPS; the result helps decide whether immunotherapy is considered and in what combination.

How it appears in your report

  • ‘PD-L1 (clone 22C3): TPS 60%’ — 60% of viable tumor cells are stained.
  • ‘PD-L1 CPS = 15’ — a combined score that also counts immune cells.
  • ‘TPS < 1%’ — no PD-L1 expression detected.
  • ‘Specimen inadequate: fewer than 100 tumor cells’ — scoring requires at least 100 viable tumor cells.

The clone is the specific antibody used. Different clones and test kits are linked to different drugs, which is why the report names them.

What it means

Score How it is calculated Example of use
TPS share of stained tumor cells among all viable tumor cells, % non-small cell lung cancer: ≥ 1% means expression, ≥ 50% means high expression
CPS number of stained cells (tumor cells, lymphocytes, macrophages) per 100 tumor cells; reported up to a maximum of 100 triple-negative breast cancer uses a CPS ≥ 10 cutoff; other tumors have their own cutoffs

The cutoff always depends on the tumor type and the specific drug. A number without the diagnosis and the method behind it tells you very little.

Does it affect treatment

Yes. In non-small cell lung cancer without EGFR or ALK alterations, the PD-L1 level helps choose between single-drug immunotherapy and a combination with chemotherapy. In triple-negative breast cancer, CPS ≥ 10 is a requirement for one immunotherapy option in metastatic disease. A high PD-L1 does not replace testing for mutations. Your treating doctor makes the decision.

Questions to ask your doctor

  • Was my result reported as TPS or CPS, and with which test?
  • Which cutoff matters for my diagnosis and the proposed regimen?
  • Were mutations checked before immunotherapy was discussed?

More in the articles on immunotherapy and on mutations in lung cancer. I can help you interpret the result in a consultation.

Sources

  1. PD-L1 IHC 22C3 pharmDx Interpretation Manual — NSCLC — Agilent (FDA-approved test), accessed 2026
  2. FDA expands pembrolizumab indication for first-line treatment of NSCLC (TPS ≥1%) — U.S. FDA, 2019
  3. FDA Grants Accelerated Approval to Pembrolizumab for Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer — The ASCO Post, 2020
  4. PD-L1 (Stains & CD markers) — PathologyOutlines, accessed 2026

FAQ

Related terms

This is reference information and not a substitute for medical advice. Your doctor interprets each value in the context of your whole situation.

Related articles

All blog articles